NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGV
Post# of 50
(Total Views: 216)
Posted On: 10/05/2023 3:56:36 PM
NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Reports Top-Line Results for Phase 2a Lomecel-B Clinical Trial
Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has released top-line results for its phase 2a trial of its investigational product Lomecel-B(TM). The study evaluated Lomecel-B for the treatment of mild Alzheimer’s disease. According to the report, the primary endpoint of safety was met across all study groups; in addition, the secondary endpoint of change from baseline to week 39 in Composite Alzheimer’s Disease Score (“CADS”) also demonstrated positive results. The report also noted that other doses demonstrated numerical slowing/prevention of disease worsening relative to placebo.
“We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” said Longeveron CEO Wa’el Hashad in the press release. “We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B in this study population. With our phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our phase 2 program in Aging-Related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has released top-line results for its phase 2a trial of its investigational product Lomecel-B(TM). The study evaluated Lomecel-B for the treatment of mild Alzheimer’s disease. According to the report, the primary endpoint of safety was met across all study groups; in addition, the secondary endpoint of change from baseline to week 39 in Composite Alzheimer’s Disease Score (“CADS”) also demonstrated positive results. The report also noted that other doses demonstrated numerical slowing/prevention of disease worsening relative to placebo.
“We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” said Longeveron CEO Wa’el Hashad in the press release. “We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B in this study population. With our phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our phase 2 program in Aging-Related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)